Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2024-09-17 Regulatory Filings
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Warunkowe przyznanie patentu przez Japoński Urząd Patentowy dotyczącego procesu wytwarzania antygenowo-specyficznych limfocytów T-regulatorowych - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is very short (773 characters) and announces a specific, non-financial event: the receipt of a conditional patent decision from the Japanese Patent Office regarding a specific medical process. This is a material event disclosure. It does not fit the definitions for 10-K, ER, IR, or AGM-R. Since it is a specific regulatory/legal development concerning intellectual property, it is best classified as a general Regulatory Filing (RNS) as it doesn't precisely match LTR (Legal Proceedings Report) or CAP (Financing Update). Given the nature of the announcement (patent decision), RNS is the most appropriate general regulatory disclosure category.
2024-09-17 Polish
Warunkowe przyznanie patentu przez USPTO w projekcie terapii opartych na CAR-TREG w leczeniu chorób neurodegeneracyjnych - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a brief announcement in Polish regarding an update on a patent application related to CAR-TREG therapies. It references a previous current report ('raport bieżący') and informs the reader about the conditional decision by the United States Patent and Trademark Office (USPTO) to grant a patent to AZTherapies, for which PolTREG holds an exclusive license. This is a specific update concerning intellectual property and licensing rights, which falls under general regulatory announcements or updates on significant corporate events that are not explicitly covered by other categories like M&A, Financing, or Director's Dealing. Given its nature as a specific, material update that doesn't fit the comprehensive definitions of 10-K, IR, or ER, and since it is not merely announcing the publication of a larger report (RPA), the most appropriate fallback category is Regulatory Filings (RNS), as it is a specific, material regulatory/legal update.
2024-09-13 Polish
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Audit Report / Information Classification · 98% confidence The document is titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU" (Independent Auditor's Review Report) concerning the "śródrocznego skróconego sprawozdania finansowego" (interim condensed financial statement) for the period ending 30.06.2024. This explicitly describes an Audit Report or review related to interim financial data, not the full annual report (10-K) or a general earnings release (ER). The content focuses on the scope of the review and the resulting conclusion based on International Accounting Standard 34 (Interim Financial Reporting). This aligns perfectly with the definition for Audit Report / Information (AR). The document length is short (3296 chars), but it is the report itself (the auditor's conclusion), not an announcement of a report, so RPA/RNS is less appropriate than AR. H1 2024
2024-09-12 Polish
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czerwca 2024 roku
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for the period 01.01.2024 to 30.06.2024. It contains detailed financial data, including a balance sheet and income statement for the first half of the year, and includes a management discussion of business activities, risks, and financial performance. As it covers a period shorter than a full fiscal year and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-12 Polish
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2024 roku
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Śródroczne skrócone sprawozdanie finansowe' (Interim condensed financial report) for the period 01.01.2024 to 30.06.2024. It contains detailed financial statements, including the statement of financial position, statement of comprehensive income, statement of changes in equity, and statement of cash flows, along with extensive explanatory notes. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2024
2024-09-12 Polish
Warunkowe przyznanie patentu przez Chińską Krajową Administracji ds. Własności Intelektualnej w projekcie leczenia stwardnienia rozsianego - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is a brief announcement (851 characters) from a Polish company (PolTREG S.A.) regarding receiving a conditional patent grant decision from the China National Intellectual Property Administration for a drug related to multiple sclerosis treatment. This is a specific update concerning intellectual property rights and regulatory/legal progress, but it is not a full financial report (10-K, IR), an earnings release (ER), or a management change (MANG). It is an announcement about a specific legal/IP event. Given the options, 'Legal Proceedings Report' (LTR) often encompasses significant legal/regulatory milestones like patent grants/disputes, although 'Regulatory Filings' (RNS) is a fallback. Since this is a specific, material update on an asset (patent), LTR is the most fitting specific category, as it relates to the protection of intellectual property which is a key legal asset/matter. However, since it is a positive announcement about IP acquisition rather than a dispute or proceeding, and given the short nature, RNS (General Regulatory Filings) is also plausible. Reviewing the definitions, LTR is for 'significant lawsuits, regulatory actions, or legal matters'. A patent grant is a significant legal/IP matter. I will classify it as LTR due to the focus on intellectual property rights acquisition.
2024-09-09 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.